Literature DB >> 14998914

Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes.

Catherine M Dalton1, Declan T Chard, Gerard R Davies, Katherine A Miszkiel, Dan R Altmann, Kryshani Fernando, Gordon T Plant, Alan J Thompson, David H Miller.   

Abstract

While brain atrophy occurs early in the clinical course of multiple sclerosis, exactly how early, which tissues are affected and the rate at which early atrophy occurs are unclear. Regional brain atrophy was investigated in 58 patients recruited within 3 months of onset of a clinically isolated syndrome (CIS) suggestive of multiple sclerosis, who were followed-up for 3 years. At 3 years, 31 subjects had developed multiple sclerosis as defined by the McDonald criteria, while 27 had not (13 had MRI-visible brain lesions and 14 did not). In those who developed multiple sclerosis, the mean decrease in grey matter fractional volume (GMF, as a fraction of total intracranial volume) was -0.017 (-3.3%) and was significantly larger than in the combined lesion-positive and lesion-negative CIS subjects [-0.005 (-1.1%), P = 0.001]. No decrease in white matter fractional volumes (WMF) was seen. Change in GMF correlated only modestly with the change in T2 lesion volume from baseline to year 3 (r = -0.428, P = 0.004). These results suggest that progressive grey matter, but not white matter, atrophy is seen in the earliest clinically observable stages of relapse onset multiple sclerosis, and this is only moderately related to lesion accumulation. Longer-term follow-up is required to determine whether early grey matter atrophy is associated with subsequent disability or cognitive impairment.

Entities:  

Mesh:

Year:  2004        PMID: 14998914     DOI: 10.1093/brain/awh126

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  103 in total

Review 1.  What do we know about the mechanism of action of disease-modifying treatments in MS?

Authors:  Hans-Peter Hartung; Amit Bar-Or; Yannis Zoukos
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

2.  Gray matter pathology in MS: a 3-year longitudinal study in a pediatric population.

Authors:  M Calabrese; D Seppi; C Romualdi; F Rinaldi; S Alessio; P Perini; P Gallo
Journal:  AJNR Am J Neuroradiol       Date:  2012-03-15       Impact factor: 3.825

Review 3.  Pharmacological treatment of early multiple sclerosis.

Authors:  Olaf Stüve; Jeffrey L Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Journal:  Drugs       Date:  2008       Impact factor: 9.546

4.  MRI quantification of gray and white matter damage in patients with early-onset multiple sclerosis.

Authors:  P Tortorella; M A Rocca; D M Mezzapesa; A Ghezzi; L Lamantia; G Comi; M Filippi
Journal:  J Neurol       Date:  2006-03-06       Impact factor: 4.849

5.  Longitudinal evaluation of clinically early relapsing-remitting multiple sclerosis with diffusion tensor imaging.

Authors:  Waqar Rashid; Andreas Hadjiprocopis; Gerard Davies; Collette Griffin; Declan Chard; Michaela Tiberio; Dan Altmann; Claudia Wheeler-Kingshott; Dan Tozer; Alan Thompson; David H Miller
Journal:  J Neurol       Date:  2008-03-20       Impact factor: 4.849

6.  A brain magnetization transfer MRI study with a clinical follow up of about four years in patients with clinically isolated syndromes suggestive of multiple sclerosis.

Authors:  Antonio Gallo; Marco Rovaris; Beatrice Benedetti; Maria Pia Sormani; Roberto Riva; Angelo Ghezzi; Vittorio Martinelli; Andrea Falini; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2007-02-14       Impact factor: 4.849

7.  A 3-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stage of MS.

Authors:  Marco Rovaris; Elda Judica; Antonia Ceccarelli; Angelo Ghezzi; Vittorio Martinelli; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2008-06-13       Impact factor: 4.849

Review 8.  Estrogen anti-inflammatory activity in brain: a therapeutic opportunity for menopause and neurodegenerative diseases.

Authors:  Elisabetta Vegeto; Valeria Benedusi; Adriana Maggi
Journal:  Front Neuroendocrinol       Date:  2008-04-29       Impact factor: 8.606

Review 9.  Imaging as an Outcome Measure in Multiple Sclerosis.

Authors:  Daniel Ontaneda; Robert J Fox
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

10.  White matter hemodynamic abnormalities precede sub-cortical gray matter changes in multiple sclerosis.

Authors:  Andrew W Varga; Glyn Johnson; James S Babb; Joseph Herbert; Robert I Grossman; Matilde Inglese
Journal:  J Neurol Sci       Date:  2009-01-31       Impact factor: 3.181

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.